Display options
Share it on

Front Neurol. 2017 Mar 01;8:65. doi: 10.3389/fneur.2017.00065. eCollection 2017.

Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS).

Frontiers in neurology

Gustavo Saposnik, Angel P Sempere, Daniel Prefasi, Daniel Selchen, Christian C Ruff, Jorge Maurino, Philippe N Tobler

Affiliations

  1. Division of Neurology, Stroke Outcomes and Decision Neuroscience Research Unit, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Zurich, Switzerland; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  2. Department of Neurology, Hospital General Universitario de Alicante , Alicante , Spain.
  3. Neuroscience Area, Medical Department, Roche Farma , Madrid , Spain.
  4. Division of Neurology, Stroke Outcomes and Decision Neuroscience Research Unit, Department of Medicine, St. Michael's Hospital, University of Toronto , Toronto, ON , Canada.
  5. Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich , Zurich , Switzerland.

PMID: 28298899 PMCID: PMC5331032 DOI: 10.3389/fneur.2017.00065

Abstract

OBJECTIVES: Limited information is available on physician-related factors influencing therapeutic inertia (TI) in multiple sclerosis (MS). Our aim was to evaluate whether physicians' risk preferences are associated with TI in MS care, by applying concepts from behavioral economics.

DESIGN: In this cross-sectional study, participants answered questions regarding the management of 20 MS case scenarios, completed 3 surveys, and 4 experimental paradigms based on behavioral economics. Surveys and experiments included standardized measures of aversion ambiguity in financial and health domains, physicians' reactions to uncertainty in patient care, and questions related to risk preferences in different domains. The primary outcome was TI when physicians faced a need for escalating therapy based on clinical (new relapse) and magnetic resonance imaging activity while patients were on a disease-modifying agent.

RESULTS: Of 161 neurologists who were invited to participate in the project, 136 cooperated with the study (cooperation rate 84.5%) and 96 completed the survey (response rate: 60%). TI was present in 68.8% of participants. Similar results were observed for definitions of TI based on modified Rio or clinical progression. Aversion to ambiguity was associated with higher prevalence of TI (86.4% with high aversion to ambiguity vs. 63.5% with lower or no aversion to ambiguity;

CONCLUSION: TI is a common phenomenon affecting nearly 7 out of 10 physicians caring for MS patients. Higher prevalence of TI was associated with physician's strong aversion to ambiguity and low tolerance of uncertainty.

Keywords: decision-making; disease-modifying therapy; multiple sclerosis; neuroeconomics; risk aversion

References

  1. Can J Neurol Sci. 2013 May;40(3):307-23 - PubMed
  2. Ann Neurol. 2013 Jan;73(1):95-103 - PubMed
  3. Med Decis Making. 2015 May;35(4):539-57 - PubMed
  4. Mult Scler. 2013 Apr;19(5):605-12 - PubMed
  5. Hypertension. 2006 Mar;47(3):345-51 - PubMed
  6. BMC Neurol. 2016 May 04;16:58 - PubMed
  7. J Neurophysiol. 2010 Feb;103(2):1036-47 - PubMed
  8. Clin Ther. 2003 Jun;25(6):1750-64 - PubMed
  9. J Neurol Sci. 2014 Apr 15;339(1-2):196-206 - PubMed
  10. Diabetes Metab. 2014 Sep;40(4):241-5 - PubMed
  11. Mult Scler. 2009 Oct;15(10):1175-82 - PubMed
  12. Am J Obstet Gynecol. 2014 Dec;211(6):692.e1-6 - PubMed
  13. Nat Rev Neurol. 2013 Sep;9(9):504-12 - PubMed
  14. Neurologia. 2017 Mar;32(2):113-119 - PubMed
  15. Can J Neurol Sci. 2016 Jan;43(1):33-43 - PubMed
  16. J Neurosci. 2009 Oct 7;29(40):12574-83 - PubMed
  17. JAMA. 2011 Jul 27;306(4):383; author reply 383-4 - PubMed
  18. Neurology. 2014 Jul 15;83(3):278-86 - PubMed
  19. Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381 - PubMed
  20. Ann Intern Med. 2008 May 20;148(10):717-27 - PubMed
  21. Value Health. 2014 Jul;17 (5):655-9 - PubMed
  22. Ann Intern Med. 2016 Jan 19;164(2):114-9 - PubMed
  23. Neurology. 2016 Jul 12;87(2):134-40 - PubMed
  24. Med Teach. 2015 Feb;37(2):153-61 - PubMed
  25. Ann Intern Med. 2001 Nov 6;135(9):825-34 - PubMed
  26. J Health Econ. 2008 Sep;27(5):1260-74 - PubMed
  27. J Pers Soc Psychol. 2000 Dec;79(6):995-1006 - PubMed
  28. Med Care. 1990 Aug;28(8):724-36 - PubMed
  29. J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):918-26 - PubMed
  30. Nat Rev Neurol. 2015 Oct;11(10):597-606 - PubMed
  31. Mult Scler. 2014 Apr;20(5):566-76 - PubMed
  32. Nat Neurosci. 2008 Apr;11(4):398-403 - PubMed
  33. J Clin Pharmacol. 2015 Jan;55(1):17-24 - PubMed
  34. Stroke. 2014 Jul;45(7):2144-50 - PubMed
  35. Am J Manag Care. 2013 Nov;19(17 Suppl):s321-31 - PubMed
  36. Mult Scler. 2012 Jan;18(1):64-71 - PubMed

Publication Types